BEIJING, Dec. 15 Sinovac Biotech Ltd. (Nasdaq: SVA),a leading provider of biopharmaceutical products in China, announced todaythat Weidong Yin, Chairman, President & CEO, was selected by China CentralTelevision (CCTV) to be one of 18 nominees for China's 2009 EconomicMan-of-the-Year.
CCTV's Economic Man-of-the-Year is the country's most influential andwell-known business award, sometimes referred to as the "Oscar Award of theChinese Economy." The award is granted to those business leaders who exemplifyChina's economic growth, are central to the Chinese economy in the currentyear, and represent role models of the Chinese economy.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "For me,it's unexpected to be nominated for China's 2009 Economic Man-of-the-Year. AndI am pleased to have it on my personal record. It also demonstrates that thecontributions made by Sinovac, represented by me, to Chinese society has beenrecognized and appreciated by the public. Sinovac's management will continueto execute our business development strategy in this favorable environment andwe are confident on our performance and growth. We will continue to makeefforts to maximize our shareholders' interests."
The award's criteria include creativity, driving force, vision, and socialresponsibility. The nominees include Yu Minhong (Michael Yu), CEO of NewOriental Group and Cao Guowei (Charles Chao), CEO of Sina.com, among others.The final results will be announced on Dec. 23, 2009. Winners are chosen by apanel of expert judges, aided by votes from the public via the Internet.
Previous recipients of the Economic Man-of-the-Year award included LinYifu, World Bank Senior Vice President and Chief Economist; Liu Chuanzhi,Chairman of Lenovo; and Li Yanhong (Robin Li), president of Baidu.com.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccineproducts include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A andB), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemicinfluenza vaccine (H5N1) and H1N1 vaccine, have already been approved forgovernment stockpiling. Sinovac is developing vaccines for enterovirus 71,universal pandemic influenza, Japanese encephalitis, and human rabies. Itswholly owned subsidiary, Tangshan Yian, is conducting field trials forindependently developed inactivated animal rabies vaccine.
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that are nothistorical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in anyforward-looking statement. Sinovac does not undertake any obligation to updateany forward-looking statement, except as required under applicable law.For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: [email protected]
Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: [email protected] [email protected]
Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email: [email protected]
SOURCE Sinovac Biotech Ltd.